Yizhao Chen and colleagues developed CAR-M targeting HER2 and CD47, demonstrating their inhibitory effects on HER2 or CD47-positive ovarian cancer in vitro and in vivo237. This evidence concerns the gene ERBB2 and ovarian carcinoma.